文献速递冠心病血脂与心血管预防

脂蛋白(a)与动脉粥样硬化斑块进展的关联

Association of Lipoprotein(a) With Atherosclerotic Plaque Progression.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

本研究在191例晚期稳定性冠心病患者中,于基线和12个月行冠状动脉CT血管造影,评估脂蛋白(a)[Lp(a)]与斑块进展的关系。高Lp(a)定义为≥70 mg/dL。结果显示高Lp(a)患者低衰减斑块(坏死核心)进展加速,而总斑块、钙化斑块和非钙化斑块体积进展无差异。

要点

  • 高Lp(a)(≥70 mg/dL)与低衰减斑块(坏死核心)体积加速进展相关。
  • Lp(a)每升高50 mg/dL,低衰减斑块体积增加10.5%(95%CI 0.7%-20.3%)。
  • 总斑块、钙化斑块和非钙化斑块体积进展与Lp(a)无关。

核心结论

  • 在晚期稳定性冠心病患者中,Lp(a)与冠状动脉低衰减斑块(坏死核心)加速进展相关,可能解释Lp(a)与心肌梗死高残余风险的关联,支持Lp(a)作为动脉粥样硬化治疗靶点。

研究设计与样本

  • 研究纳入191例接受基线及12个月冠状动脉CT血管造影的晚期稳定性冠心病患者,中位年龄65.9±8.3岁,男性152例(80%)。
  • 高Lp(a)组中位Lp(a)为100 mg/dL(范围82-115),低Lp(a)组为10 mg/dL(范围5-24)。
  • 采用线性回归分析评估Lp(a)与斑块进展的关系,调整体重指数、节段累及评分和ASSIGN评分。

主要发现

  • 基线时两组冠状动脉疾病严重程度和斑块负荷无差异。
  • 高Lp(a)组低衰减斑块进展为26.2±88.4 mm³,低Lp(a)组为-0.7±50.1 mm³(P=0.020)。
  • 多变量线性回归显示Lp(a)与低衰减斑块体积进展相关(每50 mg/dL Lp(a),β=10.5%增加,95%CI 0.7%-20.3%)。
  • 总斑块、钙化斑块和非钙化斑块体积进展在两组间无差异。

关键数值与推荐

  • 高Lp(a)定义为Lp(a)≥70 mg/dL。
  • 低衰减斑块进展:高Lp(a)组26.2±88.4 mm³ vs 低Lp(a)组-0.7±50.1 mm³,P=0.020。
  • 多变量线性回归:每50 mg/dL Lp(a)增加,低衰减斑块体积β=10.5%(95%CI 0.7%-20.3%)。

临床怎么用

  • 对晚期稳定性冠心病患者,可考虑检测Lp(a)以识别低衰减斑块快速进展的高风险个体。
  • Lp(a)≥70 mg/dL提示坏死核心进展风险增加,支持将Lp(a)作为潜在治疗靶点。

局限性

  • 样本量较小(191例),随访12个月,仅纳入晚期稳定性冠心病患者。
  • 观察性设计,不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lipoprotein(a) [Lp(a)] is associated with increased risk of myocardial infarction, although the mechanism for this observation remains uncertain. OBJECTIVES: This study aims to investigate whether Lp(a) is associated with adverse plaque progression. METHODS: Lp(a) was measured in patients with advanced stable coronary artery disease undergoing coronary computed tomography angiography at baseline and 12 months to assess progression of total, calcific, noncalcific, and low-attenuation plaque (necrotic core) in particular. High Lp(a) was defined as Lp(a) ≥ 70 mg/dL. The relationship of Lp(a) with plaque progression was assessed using linear regression analysis, adjusting for body mass index, segment involvement score, and ASSIGN score (a Scottish cardiovascular risk score comprised of age, sex, smoking, blood pressure, total and high-density lipoprotein [HDL]-cholesterol, diabetes, rheumatoid arthritis, and deprivation index). RESULTS: A total of 191 patients (65.9 ± 8.3 years of age; 152 [80%] male) were included in the analysis, with median Lp(a) values of 100 (range: 82 to 115) mg/dL and 10 (range: 5 to 24) mg/dL in the high and low Lp(a) groups, respectively. At baseline, there was no difference in coronary artery disease severity or plaque burden. Patients with high Lp(a) showed accelerated progression of low-attenuation plaque compared with low Lp(a) patients (26.2 ± 88.4 mm3 vs -0.7 ± 50.1 mm3; P = 0.020). Multivariable linear regression analysis confirmed the relation between Lp(a) and low-attenuation plaque volume progression (β = 10.5% increase for each 50 mg/dL Lp(a), 95% CI: 0.7%-20.3%). There was no difference in total, calcific, and noncalcific plaque volume progression. CONCLUSIONS: Among patients with advanced stable coronary artery disease, Lp(a) is associated with accelerated progression of coronary low-attenuation plaque (necrotic core). This may explain the association between Lp(a) and the high residual risk of myocardial infarction, providing support for Lp(a) as a treatment target in atherosclerosis.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kaiser Y, Daghem M, Tzolos E, et al. Association of Lipoprotein(a) With Atherosclerotic Plaque Progression. J Am Coll Cardiol. 2022. PMID: 35057907. doi:10.1016/j.jacc.2021.10.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。